We advised Broncus on its IPO and HKEX listing

Davis Polk advised Broncus Holding Corporation in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The net proceeds from the offering amounted to approximately HK$1.55 billion (US$199 million) prior to exercise of the over-allotment option.

Founded in 2012, Broncus is a pioneer in the field of interventional pulmonology, providing innovative lung solutions in China and globally. Its integrated platform addresses the pain points of the existing diagnosis and treatment paradigms and significant unmet medical needs for lung diseases.

The Davis Polk corporate team included partners Yang Chu, Li He and Xuelin (Steve) Wang, associates Albert Li and Sophie Liu and registered foreign lawyers Jennifer (Yujia) Jiang, Bruce Wang and Mendtuvshin (Mendee) Enkhtaivan. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Members of the Davis Polk team are based in the Hong Kong, Beijing and London offices.

Copy link to share post